CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Inclusion Criteria:

• Age greater than or equal to 18 at the time of enrollment

• Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after priorstandard of care

• Eastern Cooperative Oncology Group performance status 0 or 1

• Adequate hematologic, renal, liver, cardiac and pulmonary organ function

Exclusion Criteria:

• Prior therapy with an anti-CD19 targeting agent

• Active or chronic graft versus host disease requiring therapy

• Prior allogeneic stem cell transplantation

• Central nervous system (CNS) lymphoma, prior CNS malignancy

• Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease orautoimmune disease with CNS involvement.

• Primary immunodeficiency

• Current or expected need for systemic corticosteroid therapy

• Current thyroid disorder. Hypothyroidism controlled with stable hormone replacementis permitted

• Other malignancy within 2 years of study entry, except curatively treatedmalignancies or malignancies with low risk of recurrence

• Unwillingness to follow extended safety monitoring